News

Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks

  • NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
    10/05/2022

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

  • NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
    09/28/2022
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

NuCana plc (NCNA) can hold. Click on Rating Page for detail.

The price of NuCana plc (NCNA) is 1.08 and it was updated on 2022-10-06 13:00:23.

Currently NuCana plc (NCNA) is in undervalued.

News
    
News

Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

  • The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
    Wed, Sep. 28, 2022

NuCana: An Intriguing 'Sum Of The Parts' Story

  • Today, we revisit a small oncology development outfit called NuCana plc for the first time in a year-and-a-half. NuCana plc has early/mid-stage assets in development as well as the chance of a significant litigation settlement at some point.
    Thu, Sep. 22, 2022

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

  • NuCana trades at a bit more than half its cash position as a result of a March 2022 sell-off, caused by the trial discontinuation of the furthest-advanced drug candidate. The company's current drug candidates, NUC-3373 and NUC-7738, show remarkable results across different solid tumors, either substantially improving chemotherapy or creating novel treatment.
    Wed, Jul. 13, 2022

Why NuCana Shares Are Rising Today?

  • Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in European Patent 2955190 through their sales of Sovaldi, Harvoni, Vosevi and.
    Mon, Jul. 11, 2022

NuCana to Participate in Two Upcoming Investor Conferences

  • EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming virtual investor conferences.
    Mon, Feb. 28, 2022
SEC Filings
SEC Filings

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 08/11/2022

NuCana plc (NCNA) - 20-F

  • SEC Filings
  • 04/27/2022

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 02/25/2022

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 02/11/2022

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 01/27/2022

NuCana plc (NCNA) - EFFECT

  • SEC Filings
  • 08/30/2021

NuCana plc (NCNA) - UPLOAD

  • SEC Filings
  • 08/25/2021

NuCana plc (NCNA) - CORRESP

  • SEC Filings
  • 08/25/2021

NuCana plc (NCNA) - F-3

  • SEC Filings
  • 08/19/2021

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 06/15/2021

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 03/08/2021

NuCana plc (NCNA) - 20-F

  • SEC Filings
  • 03/04/2021

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 02/26/2021

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 02/16/2021

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 02/12/2021

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 02/02/2021

NuCana plc (NCNA) - SC 13G

  • SEC Filings
  • 01/28/2021

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 10/28/2020

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 10/05/2020

NuCana plc (NCNA) - SC 13D

  • SEC Filings
  • 09/28/2020

NuCana plc (NCNA) - 424B5

  • SEC Filings
  • 09/17/2020

NuCana plc (NCNA) - 424B5

  • SEC Filings
  • 09/16/2020

NuCana plc (NCNA) - S-8

  • SEC Filings
  • 08/19/2020

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 06/11/2020

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 03/10/2020

NuCana plc (NCNA) - 20-F

  • SEC Filings
  • 03/10/2020

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 02/14/2020

NuCana plc (NCNA) - SC 13G

  • SEC Filings
  • 02/14/2020

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 02/12/2020

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 01/16/2020

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 09/09/2019

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 05/24/2019

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 04/15/2019

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 03/22/2019

NuCana plc (NCNA) - 20-F

  • SEC Filings
  • 03/07/2019

NuCana plc (NCNA) - SC 13G/A

  • SEC Filings
  • 02/14/2019

NuCana plc (NCNA) - SC 13G

  • SEC Filings
  • 02/14/2019

NuCana plc (NCNA) - SC 13D/A

  • SEC Filings
  • 02/14/2019
Press Releases
StockPrice Release
More Headlines
News

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

  • Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.
  • 01/24/2022

NuCana: Preparing For A Critical 2022

  • NuCana: Preparing For A Critical 2022
  • 12/07/2021

NCNA Stock: Why It Substantially Increased Today

  • The stock price of NuCana PLC (NASDAQ: NCNA) increased by over 20% during intraday trading today. This is why it happened.
  • 09/29/2021

Why Are NuCana Shares Moving Higher On Wednesday?

  • The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced the enrollment of 418 evaluable patients in the Phase 3 study, which is expected to enable the first interim analysis in 1H of 2022.
  • 09/29/2021

NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer

  • EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a Phase III study (NuTide:121) for the first-line treatment of patients with advanced biliary tract cancer. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address an unmet medical need.
  • 09/29/2021

NuCana Announces Four Poster Presentations at the ESMO Congress 2021

  • NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer
  • 09/16/2021

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

  • NuCana: The Market Continues To Overlook Its ProTide Platform Technology
  • 09/11/2021

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

  • The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalysts appeared first on InvestorPlace.
  • 08/25/2021

NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update

  • EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • 08/19/2021

NuCana: Starting A Speculative Position At An Astonishing Risk-Reward

  • NuCana has been on my watch list over the past year due to its intriguing ProTide platform technology, which could generate multiple oncology drugs that can outperform the current standard of care. The share price has been under pressure since January and has been ground into an attractive valuation. I believe there is an astonishing risk-reward at these prices.
  • 06/05/2021

NuCana Reports First Quarter 2021 Financial Results and Provides Business Update

  • Presented Encouraging Clinical Data at ASCO-GI and AACR
  • 05/19/2021

NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit

  • EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.
  • 04/28/2021

NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

  • EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana's ProTides in clinical development were presented. Summaries of the posters are described below. NUC-3373
  • 04/10/2021

NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

  • Presented Encouraging Clinical Data for NUC-3373 and NUC-7738
  • 03/04/2021

3 Biotech Stocks That Jumped Last Week

  • Find out what led to the biotech industry's biggest gains.
  • 01/17/2021

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

  • Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
  • 01/15/2021

NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

  • NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
  • 01/11/2021

NuCana Appoints Andrew Kay as Board Chairman

  • Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors
  • 12/21/2020

Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist

  • Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed
  • 11/30/2020

NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update

  • Completed Successful $ 8 0 million Public Offering
  • 11/19/2020

NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  • EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.
  • 11/17/2020

NuCana to Present at the Jefferies Virtual London Healthcare Conference

  • EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference.
  • 11/12/2020

Nigeria loses N1.2trn to ASUU strikes - Businessday NG

  • The indefinite strike, which commenced on March 29, according to sources at the National Universities Commission (NUC) is the longest in the history of ASUU strikes.
  • 10/04/2020

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

  • Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc...
  • 09/17/2020

NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update

  • EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of June 30, 2020, NuCana had cash and cash equivalents of £47.8 million compared to £47.6 million as of March 31, 2020 and £52.0 million as of December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £6.1 million for the quarter ended June 30, 2020, as compared to £4.5 million for the quarter ended June 30, 2019. Basic and diluted loss per share was £0.19 for the quarter as compared to £0.14 per share for the prior-year quarter.“We had a very productive second quarter despite the COVID-19 pandemic. While we placed a brief pause on the recruitment of new patients in April, we have since lifted that pause and our operations have experienced minimal disruption to date”, said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “We are driving recruitment in the ongoing global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer. We are also making good progress in the Phase Ib combination and Phase I monotherapy studies of NUC-3373 as well as the Phase I study of NUC-7738.”Mr. Griffith continued: “We are also excited to have three posters accepted for presentation at the ESMO Virtual Congress 2020 to be held September 19-21, 2020. We look forward to presenting additional interim clinical data from the ongoing Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-FU in patients with advanced colorectal cancer (NuTide:302). Additionally, we will present the first-ever clinical data from the ongoing Phase I study of NUC-7738 in patients with advanced solid tumors (NuTide:701). Finally, we will present a poster related to the ongoing NuTide:121 study of Acelarin plus cisplatin in patients with advanced biliary tract cancer.”The poster titles are as follows: * Poster 464P - Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)   * Poster 600TiP - A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumors (NuTide:701)   * Poster 80TiP - Global Phase 3 study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)Mr. Griffith said: “We were also pleased to have presented data at the American Association for Cancer Research in June that suggested an additional immunomodulatory mode of action for Acelarin and NUC-3373.  These data showed our ProTides’ potential to alter tumor biology and enhance the activity of immune checkpoint inhibitors. They also revealed new and exciting modes of action and help explain why our ProTides appear to be such potent anti-cancer agents.”Mr. Griffith concluded: “As we continue to advance our novel ProTide pipeline, we remain fortunate to be in a strong financial position with our cash runway still expected to extend at least into the fourth quarter of 2021.  We remain focused on advancing our novel ProTide pipeline to develop more effective and safer medicines for patients with cancer.”Anticipated 2020 Milestones * Acelarin is a ProTide transformation of gemcitabine. In 2020, NuCana expects to:   * Drive enrollment in the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.   * NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2020, NuCana expects to:   * Report data from the ongoing Phase Ib study (NuTide:302) of NUC-3373 in patients with advanced colorectal cancer and establish the recommended Phase II dose of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan. * Contingent on regulatory guidance and other factors, initiate a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer. * Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.   * NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine. In 2020, NuCana expects to:   * Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.About NuCana plcNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the amount and sufficiency of the Company’s current cash and cash equivalents to fund its planned operations at least into the fourth quarter of 2021; the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. Unaudited Condensed Consolidated Statements of Operations   For the three months ended June 30, For the six months ended June 30,   2020 2019  2020 2019    (in thousands, except per share data)   £ £  £ £  Research and development expenses (5,863)(5,356) (11,801)(9,706) Administrative expenses (1,629)(1,462) (3,238)(2,808) Net foreign exchange gains (losses) 84 943  2,211 (37) Operating loss (7,408)(5,875) (12,828)(12,551) Finance income 64 297  208 616  Loss before tax  (7,344)(5,578) (12,620)(11,935) Income tax credit 1,283 1,108  2,593 2,108  Loss for the period (6,061)(4,470) (10,027)(9,827)                 Basic and diluted loss per share (0.19)(0.14) (0.31)(0.
  • 08/19/2020

Should You Buy NuCana (NCNA) Ahead of Earnings?

  • NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
  • 08/18/2020

Should your next computer be a mini PC? These are your best options.

  • Windows PCs come in all shapes and sizes, and whatever your needs there's a computer out there to suit you. Here are the best to choose from if you're looking for a new mini PC.
  • 08/07/2020

What Kind Of Shareholders Hold The Majority In NuCana plc's (NASDAQ:NCNA) Shares?

  • A look at the shareholders of NuCana plc (NASDAQ:NCNA) can tell us which group is most powerful. Institutions often...
  • 08/05/2020

Enanta Pharmaceuticals Inc (ENTA) Q3 2020 Earnings Call Transcript | The Motley Fool

  • ENTA earnings call for the period ending June 30, 2020.
  • 08/05/2020

NUC says 32 universities involved in research to tackle impacts of COVID-19

  • The Executive Secretary, National Universities Commission (NUC), Prof. Abubakar Rasheed, says 32 federal, state and private universities
  • 08/05/2020

COVID-19: How we're preparing to reopen universities — NUC

  • NUC, Tuesday, said preparations were in top gear to reopen the nation's universities after closure as a result of the outbreak of Coronavirus
  • 08/04/2020

NUC gives Nigeria varsities till August 5 to show readiness to reopen - Businessday NG

  • National Universities Commission (NUC) has given all the Federal, State, and Private Universities till Wednesday, August 5 2020 to complete a template...
  • 08/04/2020

Oppenheimer: These 3 “Strong Buy” Stocks Have Over 50% Upside Potential

  • Despite COVID-19’s devastating impact on the economy, Oppenheimer’s Chief Investment Strategist John Stoltzfus remains overweight on U.S. equities, and is more bullish on cyclical sectors versus defensive sectors. As for the legitimate concerns about the virus’ re-emergence, Stolzfus argues investors should “consider the reopening setbacks as just that and not something that is permanent.” "In the past week along with legitimate concerns about the recent resurgences of Covid-19 stateside and abroad there was also a resurgence of the “life will never be the same” kind of worry creeping into the theme du jour. We don’t attribute much value to the latter worry as collaborative efforts by scientists across the globe continue at record pace to pursue vaccines to stem the spread of the virus as well as drugs of greater efficacy to treat those who have fallen ill to it," Stoltzfus noted.Applying Stolzfus’ take to its recommendations, Oppenheimer is pounding the table on three stocks in particular. Noting that all three have solid long-term growth prospects, the firm’s analysts believe each has at least 50% upside potential. After running the tickers through TipRanks’ database, it’s clear the rest of the Street is in agreement, with each earning a “Strong Buy” consensus rating.   NuCana PLC (NCNA)Using its ProTide technology, NuCana is working on transforming some of the most widely prescribed chemotherapy agents and nucleoside analogs into more effective and safer medicines. Given its potential to address the key limitations of other therapies, Oppenheimer has high hopes for this healthcare name.Representing the firm, 5-star analyst Leland Gershell points out that nucleoside analogs are commonly used treatments for viral infections and many cancers, but “cellular resistance mechanisms that impede drug entry and activation, as well as enhance breakdown and toxicity, hamper the fuller realization of their therapeutic potential.” NCNA’s technology, on the other hand, uses a prodrug strategy exemplified by Gilead’s HIV and HCV programs to address these issues.NCNA’s lead asset, Acelarin, is in Phase 3 development for front-line biliary tract cancer after the therapy combined with cisplatin demonstrated a superior clinical efficacy signal compared to gemcitabine, the current standard-of-care. “These combinations are being compared head-to-head in a recently initiated Phase 3 in front-line disease, and interim efficacy analyses expected 2022-23 could enable this orphan indication's first approval,” Gershell commented. "We assign a 50% probability of success for Acelarinin biliary tract cancer, assume 35% peak penetration of the target ~18K patient annual incidence, with peak 2028 sales of ~$319M."Adding to the good news, investors could get an update on NUC-3373, NuCana’s second product in clinical development, in the second half of 2020. NUC-3373 is an optimized active metabolite of 5- fluorouracil which is moving towards a registrational Phase 2/3 trial in early-line colorectal cancerLooking at the available data, compared to 5-FU, NUC-3373 was able to generate significantly more anti-cancer activity, required a lower infusion time and had a better tolerability profile. On top of this, a Phase 1b multiple combination therapy trial in advanced colorectal cancer showed the candidate might benefit patients that are refractory to 5-FU, a claim Gershell believes could be validated by the 2H20 results. The implication? Gershell stated, “With 5-FU a standard treatment component for a wide range of cancers, NUC-3373's key advantages position it to become the preferred alternative among the 500,000 U.S. individuals who receive 5-FU annually. Beyond colorectal cancer, NCNA has indicated interest in exploring NUC-3373 in other malignancies treated with 5- FU (e.g., gastric, esophageal cancer).”To this end, Gershell rates NCNA an Outperform (i.e. Buy) along with a $20 price target. Shares could appreciate by 295%, should the analyst’s thesis play out in the coming months. (To watch Gershell’s track record, click here) It’s not often that the analysts all agree on a stock, so when it does happen, take note. NCNA’s Strong Buy consensus rating is based on a unanimous 4 Buys. The stock’s $17 average price target suggests a 236% upside from the current share price of $5.08. (See NCNA stock analysis on TipRanks)Milestone Pharmaceuticals (MIST)Hoping to address the unmet needs of patients, Milestone Pharmaceuticals develops therapies for the acute treatment of arrhythmias and other cardiac conditions. Even though the company experienced a setback related to one of its therapies in March, Oppenheimer believes it is back on track.5-star analyst Leland Gershell, who also covers NCNA, acknowledges that there was some uncertainty following NODE-301's primary endpoint miss in March. However, he argues “MIST has emerged from constructive FDA discussions on track to complete etripamil's development in paroxysmal supraventricular tachycardia (PSVT) without the need to run a new trial, a solid positive to expectations.”Although NODE-301 wasn’t able to meet the original primary endpoint of time to conversion (TTC), statistical analysis demonstrated that the therapy showed efficacy earlier on when evaluated over shorter periods. Therefore, the FDA agreed to a new statistical analysis plan that defines the primary endpoint as TTC at 30 minutes, so NODE-301 was technically successful. What does this change mean for MIST? Gershell noted, “NODE-301's original five-hour primary analysis period provided time for a sufficient number of placebo subjects to experience spontaneous resolutions, precluding the ability to show a difference. The use of a 30-minute window as the primary assessment retains etripamil nasal spray's value proposition to avoid/reduce emergency department visits, and bodes well for RAPID success.”Originally, the RAPID study (formerly NODE-301B) was set to include 170 participants who had been randomized into the double-blind, event-driven trial but had not experienced an SVT event upon reaching the target event number. Now, the trial will continue until 180 total events have been witnessed, and MIST will re-open enrollment in 2H20 with 1:1 randomization. With top-line data slated for release in late 2021/early 2022, the data readout could reflect a major catalyst.When it comes to its cash position, MIST boasted $102 million as of March 31, with the $25 million private placement by lead shareholder RTW supporting its operations into Q2 2022. This capital was provided in exchange for about 6.66 million pre-funded stock warrants. According to Gershell, this means MIST should have enough funding to reach key catalysts.All of the above makes it clear why Gershell is now standing with the bulls. In addition to upgrading the rating to Outperform, he put an $18 price target on the stock. This brings the upside potential to 117%.Judging by the consensus breakdown, other analysts also like what they’re seeing. 3 Buys and a single Hold add up to a Strong Buy consensus rating. Based on the $13.25 average price target, the upside potential lands at 59%. (See MIST stock analysis on TipRanks)InterDigital (IDCC)Counting tech industry titans like Apple, Samsung, LG and Huawei as customers, InterDigital is one of the top R&D companies in the world. With it boasting 32,000 patents, applications in wireless and video technologies and a broad international footprint, Oppenheimer thinks now is the time to get on board.Analyst Ian Zaffino tells clients that IDCC’s product portfolio gives it “significant earnings power.” Expounding on this, he stated, “Its patents are integrated into the major wireless standards and comprise ~6% of all 5G patents, including ones that cover signal power control... Roughly 93% of revenues come from fixed-fee payments, which create a predictable and recurring revenue stream.”Additionally, the company has a history of IP enforcement. Speaking to its efforts on this front, IDCC signed agreements with Samsung in 2014, Apple in 2016 and LG Electronics in 2017. It should be noted that the tech name recently renewed its license with Huawei, which could open the door for licensing deals with other handset makers, in Zaffino’s opinion.Currently, there are five Chinese manufacturers, including Oppo, Xiaomi, Vivo, Lenovo and TCL, as well as a group of smaller players that use IDCC’s technology without a license. “Over the next several years, we believe the company can ink deals with each one. If we assume each large manufacturer represents ~$30 million-$40 million of annual revenues, IDCC has the potential to generate revenues of ~$500 million and EPS of ~$6,” Zaffino explained.Representing another positive, IDCC recently acquired Technicolor, a move that could pay off big time. According to Zaffino, revenues here would most likely come from “major television manufacturers, including Samsung and LG, who already have relationships with IDCC on the wireless side.” The company also has an opportunity in the IoT space.Everything that IDCC has going for it prompted Zaffino to rate the stock an Outperform (i.e. Buy). The cherry on top? His $90 price target implies a 53% upside from current levels. (To watch Zaffino’s track record, click here) Other analysts back Zaffino’s take. 3 Buys and no Holds or Sells have been assigned in the last three months, so the word on the Street is that IDCC is a Strong Buy. The $94.67 average price target puts the upside potential at 60%. (See InterDigital stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
  • 07/31/2020

Best PCs (Updated 2020)

  • Have you been looking for a personal computer for your home or work area? If so, check out this list of the best PCs that you can find in 2020.
  • 07/27/2020

Benzinga's Top Upgrades, Downgrades For July 24, 2020

  • Upgrades * Macquarie upgraded the previous rating for Taiwan Semiconductor Manufacturing Co Ltd (NYSE: TSM) from Neutral to Outperform. Taiwan Semiconductor earned $0.78 in the second quarter, compared to $0.41 in the year-ago quarter. The current stock performance of Taiwan Semiconductor shows a 52-week-high of $69.25 and a 52-week-low of $39.78. Moreover, at the end of the last trading period, the closing price was at $67.37. * For First Internet Bancorp (NASDAQ: INBK), Janney Capital upgraded the previous rating of Neutral to the current rating Buy. For the second quarter, First Internet had an EPS of $0.40, compared to year-ago quarter EPS of $0.60. At the moment, the stock has a 52-week-high of $28.50 and a 52-week-low of $10.47. First Internet closed at $14.92 at the end of the last trading period. * According to Wolfe Research, the prior rating for Allegiant Travel Co (NASDAQ: ALGT) was changed from Peer Perform to Outperform. For the first quarter, Allegiant Travel had an EPS of $2.05, compared to year-ago quarter EPS of $3.98. At the moment, the stock has a 52-week-high of $183.26 and a 52-week-low of $60.06. Allegiant Travel closed at $113.76 at the end of the last trading period. * Argus Research upgraded the previous rating for Tesla Inc (NASDAQ: TSLA) from Hold to Buy. In the second quarter, Tesla showed an EPS of $2.18, compared to ($1.12) from the year-ago quarter. The stock has a 52-week-high of $1794.99 and a 52-week-low of $211.00. At the end of the last trading period, Tesla closed at $1513.07. Downgrades * Craig-Hallum downgraded the previous rating for Entegris Inc (NASDAQ: ENTG) from Buy to Hold. Entegris earned $0.60 in the second quarter, compared to $0.39 in the year-ago quarter. At the moment, the stock has a 52-week-high of $71.51 and a 52-week-low of $38.12. Entegris closed at $69.65 at the end of the last trading period. * According to Stephens & Co., the prior rating for CoreLogic Inc (NYSE: CLGX) was changed from Overweight to Equal-Weight. In the second quarter, CoreLogic showed an EPS of $1.02, compared to $0.82 from the year-ago quarter. The stock has a 52-week-high of $69.87 and a 52-week-low of $24.69. At the end of the last trading period, CoreLogic closed at $68.32. * B of A Securities downgraded the previous rating for Icon PLC (NASDAQ: ICLR) from Buy to Neutral. In the second quarter, Icon showed an EPS of $1.20, compared to $1.69 from the year-ago quarter. The current stock performance of Icon shows a 52-week-high of $199.83 and a 52-week-low of $104.28. Moreover, at the end of the last trading period, the closing price was at $189.06. Initiations * Wolfe Research initiated coverage on Cisco Systems Inc (NASDAQ: CSCO) with an Outperform rating. The price target for Cisco Systems is set to $54.00. Cisco Systems earned $0.79 in the third quarter, compared to $0.78 in the year-ago quarter. The stock has a 52-week-high of $58.09 and a 52-week-low of $32.40. At the end of the last trading period, Cisco Systems closed at $47.41. * With a current rating of Outperform, Wolfe Research initiated coverage on F5 Networks Inc (NASDAQ: FFIV). The price target seems to have been set at $190.00 for F5 Networks. F5 Networks earned $2.23 in the second quarter, compared to $2.57 in the year-ago quarter. The current stock performance of F5 Networks shows a 52-week-high of $156.36 and a 52-week-low of $79.78. Moreover, at the end of the last trading period, the closing price was at $154.71. * Wolfe Research initiated coverage on Slack Technologies Inc (NYSE: WORK) with a Peer Perform rating. The price target for Slack Technologies is set to $32.00. For the first quarter, Slack Technologies had an EPS of ($0.02), compared to year-ago quarter EPS of ($0.23). The current stock performance of Slack Technologies shows a 52-week-high of $40.07 and a 52-week-low of $15.10. Moreover, at the end of the last trading period, the closing price was at $30.33. * Wolfe Research initiated coverage on Twilio Inc (NYSE: TWLO) with an Outperform rating. The price target for Twilio is set to $300.00. Twilio earned $0.06 in the first quarter, compared to $0.05 in the year-ago quarter. The current stock performance of Twilio shows a 52-week-high of $271.00 and a 52-week-low of $68.06. Moreover, at the end of the last trading period, the closing price was at $254.30. * Oppenheimer initiated coverage on NuCana PLC (NASDAQ: NCNA) with an Outperform rating. The price target for NuCana is set to $20.00. NuCana earned ($0.15) in the first quarter, compared to ($0.17) in the year-ago quarter. The current stock performance of NuCana shows a 52-week-high of $10.94 and a 52-week-low of $3.81. Moreover, at the end of the last trading period, the closing price was at $5.15. * Wolfe Research initiated coverage on Apple Inc (NASDAQ: AAPL) with an Underperform rating. The price target for Apple is set to $315.00. Apple earned $2.55 in the second quarter, compared to $2.46 in the year-ago quarter. The stock has a 52-week-high of $399.82 and a 52-week-low of $192.58. At the end of the last trading period, Apple closed at $371.38. * With a current rating of Peer Perform, Wolfe Research initiated coverage on Zoom Video Communications Inc (NASDAQ: ZM). The price target seems to have been set at $255.00 for Zoom Video Communications. In the first quarter, Zoom Video Communications showed an EPS of $0.20, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $281.00 and a 52-week-low of $60.97. At the end of the last trading period, Zoom Video Communications closed at $251.50.See more from Benzinga * Insider Buys CMG Holdings Group Stock * Insider Buys Northern Technologies' Shares * Stocks That Hit 52-Week Lows On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 07/24/2020

NuCana PLC (NASDAQ:NCNA) Receives Average Rating of “Buy” from Brokerages

  • Shares of NuCana PLC (NASDAQ:NCNA) have earned an average rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among analysts that have covered […]
  • 07/16/2020

We sacked professors, others to put best system in place – UniAbuja VC

  • The Vice-Chancellor of University of Abuja, Professor Abdul- Rasheed Na’Allah, who clocked a year in office on July 1, spoke on the journey so far and his effort to transform the university. Univer…
  • 07/16/2020

Muslim community establishes varsity in Abuja

  • A religious organisation, Muslim Community Centre (MCC), Abuja, has proposed the establishment of Monument University, Bwari, Abuja. In a statement, a member of MCC’s University Planning Committee …
  • 07/16/2020

Wrongful Dismissal: 24yrs after Court orders NUC to reinstate official

  • The National Industrial Court (NIC), Lagos division, has ordered the National Universities Commission (NUC), to immediately reinstate...
  • 07/12/2020

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC

  • Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.
  • 07/02/2020

Kickstart a home media server with Intel’s NUC 10 Mini PC at $433 (Save 24%) - 9to5Toys

  • Amazon currently offers the Intel NUC 10 i5 Performance Kit for $433.19 shipped. Saving you $127 from its going rate, today’s offer is $7 under our previous mention and marks a new all-time low. Intel’s compact NUC delivers a 10th-generation Core i5 processor alongside a 2.5-inch hard drive bay, M.2 storage slot, and room for two […]
  • 07/01/2020

Why I’d buy and hold a2 Milk shares until 2025

  • Despite their recent growth, here's why I believe a2 Milk Company Ltd (ASX: A2M) shares are a great buy and hold option for the long term.
  • 07/01/2020

IPPIS: ASUU insists on reversal of appointment, promotion during strike

  • ASUU has demanded the reversal of all appointments and promotions carried out during the ongoing strike which began a few weeks ago.
  • 06/29/2020

Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation

  • The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.
  • 06/29/2020

NUC accredits Law,13 other academic programmes in UNIABUJA

  • THE National Universities Commission, NUC,has accredited Law and 13 other academic programmes of the University of Abuja.
  • 06/29/2020

Is UNICAL vice chancellorship for sale?

  • Universities are a legacy of the twelfth century. The period was not only an age of revival in the field of learning; it was an age of new creation in the field of institutions of higher education.…
  • 06/27/2020

Critical Survey: NuCana (NASDAQ:NCNA) vs. Athersys (NASDAQ:ATHX)

  • NuCana (NASDAQ:NCNA) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk. Earnings & Valuation This table compares NuCana and Athersys’ gross revenue, earnings per share and valuation. Gross […]
  • 06/26/2020

Volleyballerin Nicole Eiholzer - Vom Sand in die Halle und gleich in die Nati

  • Im Beachvolleyball sah Nicole Eiholzer kaum noch Perspektiven. Der Wechsel zurück in die Halle zahlte sich sogleich aus.
  • 06/25/2020

Al-Qalam starts virtual lessons

  • Al-Qalam University, Katsina has launched an online lecture platform to transform learning in the COVID 19 lockdown. A statement by the institute’s Head, Public Affairs, Atiku Akilu, said the unive…
  • 06/25/2020

COVID-19: Nigeria’s school system needs decentralised learning now- EduTech - Businessday NG

  • In the wake of the ongoing COVID-19 pandemic and shutdown of schools nationwide, Olufemi Shonubi, general manager, EduTech, has called on the federal government of Nigeria to decentralise the learning process for school children, as the negative effect of the pandemic has necessitated the search for a convenient school system to strengthen learning in the […]
  • 06/22/2020

Hot Money Monday: These are the most in-demand stocks on the ASX right now - Stockhead

  • Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the level at which a company may have been …
  • 06/21/2020

Nuchev (ASX:NUC) Shares Down 1%

  • Nuchev Limited (ASX:NUC) traded down 1% on Friday . The company traded as low as A$3.09 ($2.19) and last traded at A$3.10 ($2.20), 67,638 shares traded hands during trading. The stock had previously closed at A$3.13 ($2.22). The company has a quick ratio of 13.72, a current ratio of 20.15 and a debt-to-equity ratio of […]
  • 06/20/2020

Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag

  • The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
  • 06/18/2020

‘Delay in appointment of principal officers stalls Abuja tech varsity’

  • Facilities left to rot The excitement that heralded the establishment of the Abuja University of Technology Abaji (AUTA) is beginning to wane as structures on the main campus in Abaji, a largely ru…
  • 06/18/2020

Senate Consider Bill to Decentralize Army Varsity

  • By Deji Elumoye The Senate on Tuesday canvassed for the decentralisation of the Nigerian Army University in Biu, Borno State with a view to enhancing technological development and prevention of cri…
  • 06/17/2020

Nucleus Financial Group PLC (LON:NUC) Insider David Ritchie Ferguson Buys 97 Shares

  • Nucleus Financial Group PLC (LON:NUC) insider David Ritchie Ferguson acquired 97 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average price of GBX 154 ($1.96) per share, for a total transaction of £149.38 ($190.12). David Ritchie Ferguson also recently made the following trade(s): […]
  • 06/17/2020

ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis

  • ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
  • 06/16/2020

Uyo varsity at loggerheads with host communities over land

  • Many years ago, the Federal Government acquired a vast expense of land located along Nwaniba Road as permanent site for the University of Uyo in Akwa Ibom State. The land, which traversed over 10 c…
  • 06/13/2020

Best of 9to5Toys: Best Buy 3-day event + Apple sale, 2018 12.9-inch iPad Pro $220 off, Nintendo eShop Summer Sale, more - 9to5Toys

  • In this week’s Best of 9to5Toys: Best Buy 3-day sale + Apple Shopping Event, prev. gen 12.9-inch iPad Pro gets $220 discount, Nintendo eShop Summer Sale with up to 50% off, and more… Best Buy has two sales running right now, one lasting only three days, and the other focusing specifically on Apple gear. The 3-day …
  • 06/13/2020

NOUN matriculates 15,000 students - Vanguard News

  • By Joseph Erunke ABUJA – THE National Open University of Nigeria, NOUN, Saturday, matriculated 15,000 of its newly admitted students. But the matriculation ceremony was held online following the lockdown arising from the outbreak of COVID-19 in the country. Addressing the new students during the university’s 19th matriculation ceremony, Vice-Chancellor of NOUN, Professor Abdalla UbaRead More
  • 06/13/2020

AMD vs. Intel: Which CPU is right for you? | Digital Trends

  • The decades-long AMD vs. Intel debate rages on and is now more complicated than ever. We examine the rivalry to see what CPU maker is the best for your new PC.
  • 06/12/2020

Gov. Matawalle redefining frontiers of governance, development -

  • Governor Bello Muhammad Matawalle of Zamfara state emerged when the state was on the brink of socioeconomic collapse. Before May 2
  • 06/11/2020

Immunic Gets FDA Allowance for Phase II Coronavirus Study

  • Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
  • 06/10/2020

Bundle QNAP's 2-bay NAS with two 4TB Seagate hard drives for $300 ($400 value) - 9to5Toys

  • Adorama is currently offering the QNAP TS-228A 2-Bay NAS bundled with two 4TB Seagate IronWolf Hard Drives for $299.99 shipped. Typically picking up everything included in this bundle would run you $400, with today’s offer beating the combined all-time lows by $50 and marking the best value to date. QNAP’s 2-bay NAS is a notable …
  • 06/10/2020

UNIUYO host community petitions NUC over alleged harassment, intimidation

  • The host community of University of Uyo under the auspices of Offot Usung Ifiayong Unity Assembly has petitioned the National Universities Commission (NUC) over alleged harassment and intimidation …
  • 06/08/2020

Awuzie Heads Panel for Take-off of Imo State University of Agriculture and Environmental Sciences

  • Former Vice Chancellor of Imo State University and Chairman of Academic Staff Union of Universities (ASUU), prof. Ukachukwu Awuzie has been appointed as Chairman of the Committee for the establishm…
  • 06/05/2020

Intel’s next tiny PC, the Tiger Lake NUC, could be a PS5-beating powerhouse - but at a cost

  • The catch is there may not be a more affordable alternative NUC, going by this leak
  • 06/04/2020

Best budget gaming PC 2020: top gaming desktops for less

  • These are the best budget gaming PCs of 2020
  • 06/04/2020

EduTech: How digital learning becomes necessity, not choice

  • Coronavirus COVID-19 has changed almost everything in the world. It has turned the economy upside down, ravaged health system, destroyed...
  • 06/03/2020

Why NuCana (NCNA) Stock Might be a Great Pick

  • NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
  • 06/02/2020

Is the a2 Milk share price too high to buy?

  • The A2 Milk share price has been one of the standout performers during the coronavirus crisis. Is it too late to buy in?
  • 06/02/2020

Will NuCana Continue to Surge Higher?

  • As of late, it has definitely been a great time to be an investor of NuCana
  • 06/01/2020

Top Ranked Momentum Stocks to Buy for May 28th

  • Top Ranked Momentum Stocks to Buy for May 28th
  • 05/28/2020

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

  • The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
  • 05/27/2020

NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference

  • NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference. The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
  • 05/27/2020

Intel NUC 9 Extreme (Ghost Canyon) review

  • Tiny yet mighty
  • 05/26/2020

3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year

  • Out on Wall Street, stocks were able to pull out a major win. Despite being a more volatile week of trading, the three major U.S. stock indexes were each able to notch a more than 3% weekly-gain, with the Dow Jones exhibiting its best weekly performance since April 9. The surge came as investors applauded progress related to a COVID-19 vaccine and the reopening of the U.S. economy. Against this backdrop, investor focus has locked in on one area of the market in particular: the healthcare sector. Amid the COVID-19 pandemic, the space has held up strong, broadly outperforming the rest of the market. Not to mention return-minded investors tend to flock to these names thanks to the possibility of sky-high rewards. What’s the secret to their huge return potential? The nature of the industry itself. Many healthcare companies only rely on a few key indicators such as study results or regulatory approvals to determine if there’s a clear path forward, and thus, a single piece of good news can launch it on an upward trajectory. However, the opposite also holds true, so these tickers are notoriously risky. Understanding the volatile nature of the industry, we used TipRanks’ database to pinpoint compelling plays within the healthcare space. The platform helped us track down three that have received overwhelmingly bullish support from analysts, enough to earn a “Strong Buy” consensus rating. The cherry on top? Each could double in the twelve months ahead. NuCana PLC (NCNA) Using its ProTide technology to turn some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines, NuCana hopes to improve treatment outcomes for cancer patients. With the company gearing up for a jam-packed year of potential catalysts, several members of the Street believe that now is the time to snap up shares. At the beginning of May, NCNA announced that it had restarted enrollment for its Phase 3 NuTide:121 trial, which is examining Acelarin and cisplatin in front-line biliary tract cancer (BTC) patients. Weighing in on the good news for H.C. Wainwright is five-star analyst Robert Burns. He reminds clients that the initial data from the Phase 1 ABC-08 front-line locally advanced or metastatic BTC trial, which was presented at ASCO 2019, demonstrated that within the intent-to-treat (ITT) population, the therapy produced a 50% unconfirmed objective response rate (ORR) and 7% complete response (CR) rate. “We believe this compares favorably to results that Valle and colleagues presented in their 2010 New England Journal of Medicine paper examining gemcitabine plus cisplatin (n=204) in a front-line BTC Phase 3 trial,” Burns commented. As a result, he thinks data from the trial could fuel significant upside. If that wasn’t enough, a few weeks later, NCNA revealed that enrollment for the Phase 1 and Phase 1b trials of its NUC-3373 candidate in metastatic colorectal cancer (mCRC) and in advanced solid tumors, respectively, were resumed. Enrollment for the Phase 1 NuTide:701 trial evaluating NUC-7738 in patients with advanced solid tumors also kicked off again. Early data from these trials is slated for release later this year. Burns points out that there are several other key catalysts on the horizon including the readout of data from the Phase 1b ABC-08 trial of Aclearin and cisplatin in first-line BTC, an update regarding the enrollment status for the Phase 3 trial of Acelarin and gemcitabine in first-line BTC as well as the initiation of a Phase 2/3 trial of NUC-3373 in conjunction with other agents in mCRC. Based on all of the above, Burns stayed with the bulls. Along with a Buy rating, the $16 price target remains unchanged. Should this target be met, a twelve-month gain of 173% could be in store. (To watch Burns’ track record, click here) Do other analysts agree with Burns? As it turns out, they do. With 100% Street support, or 3 Buy ratings to be exact, the message is clear: NCNA is a Strong Buy. At $16, the average price target matches Burns’. (See NuCana stock analysis on TipRanks) Celyad (CYAD) Moving right along, we come across Celyad, which is developing innovative CAR-T NK cell-based immunotherapies that could potentially treat cancer. As the second half of 2020 will feature major catalysts, it’s no wonder the analyst community is excited about this name. In the near-term, Celyad will present updated data from the Phase I alloSHRINK study of CYAD-101, its therapy designed as a treatment for mCRC, at the virtual ASCO conference on May 29 through 31. Using non-gene editing technology, the therapy has already shown anti-tumor activity in two out of twelve patients with a partial response and five patients with stable disease with a minimum of three months of duration. Representing H.C. Wainwright, five-star analyst Edward White is optimistic that the outcome will be favorable. He explained, “To date, CYAD-101 alloSHRINK has not demonstrated clinical evidence of GvHD or dose limiting toxicities.” Looking forward, CYAD will read out preliminary data from the Phase 1 THINK trial involving its candidate, CYAD-01, a CAR-T that uses natural killer cell specificity to target T-cells against a broad range of tumors, without preconditioning in patients with r/r AML and MDS, and the DEPLETHINK trial utilizing preconditioning with Cy/Flu. Both of these trials use the OptimAb manufacturing process, but White points out that the company will decide which protocol to proceed with based on the data. Some investors expressed concern after COVID-19 forced the company to push back the previously expected timing for the THINK and DEPLETHINK trial readouts, but White was unphased by the delay. “THINK data presented at the American Society of Hematology (ASH) Annual Meeting 2019 showed that 53% (8/15) of evaluable patients demonstrated anti-leukemic activity with bone marrow blasts decrease, including five patients with objective responses and one patient with stable disease (SD) for at least three months,” he stated. The analyst added, “No objective responses had been shown at the time of presentation, but safety data demonstrated that CYAD-01 manufactured with OptimAb was well tolerated following preconditioning chemotherapy.” With a decision on which protocol CYAD will pursue expected by year end 2020, the deal is sealed for White. In addition to reiterating his Buy recommendation, he kept the $37 price target as is. This target conveys his confidence in CYAD’s ability to soar 339% in the next year. (To watch White’s track record, click here) All in all, other analysts echo White’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $27.33 average price target, the upside potential comes in at 224%. (See Celyad stock analysis on TipRanks) IDEAYA Biosciences Inc. (IDYA) Last but not least we have IDEAYA, which is developing targeted oncology drugs including the PKC inhibitor, IDE196, for the treatment of metastatic uveal melanoma (MUM) as well as a portfolio of synthetic lethality drug candidates. On the heels of the acceptance of four abstracts for presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held on June 22-24, many Wall Street analysts have been impressed. Among the bulls is Oppenheimer’s Kevin DeGeeter. He tells investors that he sees two abstracts as being especially promising as both have the potential “to inform clinical studies to start within the next twelve months.” Specifically looking at abstract 1956, “In vitro and in vivo characterization of novel MAT2A allosteric inhibitors”, the five-star analyst believes it is a “placeholder and most likely potential source of upside for IDYA shares.” DeGeeter added, “Specifically, we are cautiously optimistic abstract 1956 may more fully describe the cellular anti-proliferation activity and PK profile from a scaffold of IDYA's lead synthetic lethality program, a small molecule allosteric inhibitor of MAT2A... If management opts to disclose cellular anti-proliferation activity or cellular SAM modulation data. In the absence of efficacy data, we would view clean liver tox profile as a material finding.” In addition, DeGeeter pointed out, “Our investment thesis for shares of IDYA is based in large measure on the potential of the company’s broad pipeline of synthetic lethality programs.” As a result, he argues that the selection of a development candidate for lead synthetic lethality program, MAT2A, which is slated for Q2 2020, and the IND filing expected in Q4 2020, represent key catalysts. He also thinks AACR is a “logical” timeframe to confirm selection. It should be noted previous studies have demonstrated that MAT2A regulates PMRT5 expression. To top it all off, DeGeeter believes abstract 5337 will provide more clarity regarding the magnitude of a potential synergy of IDE196 with a MEK inhibitor. The results could help IDYA select patients for a basket study of IDE196. To this end, DeGeeter left an Outperform rating and $17 price target on the stock. Given this target, shares could skyrocket 143% in the next twelve months. (To watch DeGeeter’s track record, click here) Turning now to the rest of the Street, other analysts also like what they’re seeing. 3 Buys and no Holds or Sells have been assigned in the last three months, making the consensus rating a Strong Buy. While less aggressive than DeGeeter’s, the $15 average price target still leaves room for 115% upside potential. (See IDEAYA stock analysis on TipRanks)
  • 05/24/2020

Uzodimma decries state of IMSUTH, non-accreditation of College of Medicine - Businessday NG

  • Hope Uzodimma, governor of Imo State, has decried the deplorable state of all the units and departments of the Imo State University Teaching Hospital (IMSUTH), Orlu and the entire health sector of the state. The governor was moved to tears after listening to the damning report of the Visitation Panel on Imo State University Teaching […]
  • 05/24/2020

Best of 9to5Toys: The top Memorial Day deals from Best Buy, Google, and Home Depot - 9to5Toys

  • In this week’s Best of 9to5Toys: Best Buy’s Memorial Day sale is here, Nest Cams and other smart home gear from $29, Home Depot discounts outdoor essentials, and more… Memorial Day is Monday and the sales surrounding the holiday are here. Best Buy’s Memorial Day sale is full of great and fantastic deals on a plethora …
  • 05/23/2020

Uzodimma Assents to Bill Repealing Law on Payment of Pensions, Gratuity of Ex-Governors, Speakers, Others

  • The Governor of Imo State, Senator Hope Uzodimma has accented to a Bill repealing the law that created pension allowances and gratuities to former Governors, Deputy Governors, Speakers and Deputy S…
  • 05/22/2020

The best gaming PC 2020: top desktops for PC gamers

  • These are the best gaming PCs for 2020
  • 05/22/2020

OAGF says ASUU's request, a ploy to evade tax - Businessday NG

  • The Office of the Accountant General of the Federation (OAGF) has refuted claims on salary deduction claims by tertiary institutions unions, led by the Academic Staff Union of Universities (ASUU), calling such, a cheap propaganda aimed to denigrate Integrated Payroll and Personnel Information System, IPPIS. The OAGF in a statement signed by Henshaw Ogubike, Director, […]
  • 05/19/2020

NuCana Reports First Quarter 2020 Financial Results and Provides Business Update

  • EDINBURGH, United Kingdom, May 19, 2020 (GLOBE NEWSWIRE via COMTEX) -- Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to...
  • 05/19/2020

NuCana Reports First Quarter 2020 Financial Results and Provides Business Update

  • Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020.
  • 05/19/2020

Oyo releases food advisory to boost immunity - Businessday NG

  • Governor Seyi Makinde, on Monday, released a food advisory, which he said experts have certified as immune boosters that could help the human...
  • 05/19/2020

Nigeria’s TETFund partner US Morgan state university to admit 50 Ph.D. students Annually

  • Nigeria’s TETFund has signed new agreement withUS Based Morgan state university to grant 50 Ph.D. students Annually, Naija247news has learned. MSU’s Board of Regents Approves Five-Year Agreement, B…
  • 05/18/2020

NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic

  • NuCana plc (NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer (NuTide:121) on May 5, 2020. NuCana has now also re-opened the Phase I and Phase Ib clinical studies of NUC-3373 and the Phase I clinical study of NUC-7738.
  • 05/18/2020

Turn any old screen into a home office dream PC

  • The NUC has a silly name but is a very useful tiny computer that you can attach to the back of most screens to effectively turn them into an all-in-one computer.
  • 05/18/2020

NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020

  • NuCana plc (NASDAQ:NCNA) today announced that two abstracts describing non-clinical studies related to the mechanisms of action of its proprietary ProTides, Acelarin (NUC-1031) and NUC-3373, were selected for poster presentations at the AACR Annual Meeting 2020 on June 22-24, 2020. In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.
  • 05/15/2020

'Carbon neutral computing': Intel plots path to zero waste, zero carbon computers

  • Computer chip giant's sustainability report outlines a raft of new green goals, including a pledge to send zero waste to landfill and achieve "net positive" water use.
  • 05/14/2020

PCWorld's May Digital Magazine: Ryzen 4000 vs. Comet Lake H

  • Enjoy the best of PCWorld.com in a curated Digital Magazine for Android, iOS, and your web browser.
  • 05/14/2020

The Best Desktop Computers for Small Businesses in 2020 | Digital Trends

  • Whether you need a powerful PC to get work done or an elegant system for your customer-facing operation, these are the best PCs for small businesses.
  • 05/13/2020

Assembly Biosciences, Inc. (ASMB) Assembly Biosciences' HBV Portfolio Progress Conference Call (Transcript)

  • Assembly Biosciences, Inc. (NASDAQ:ASMB) Assembly Biosciences’ HBV Portfolio Progress Conference Call May 07, 2020 04:30 PM ET Company Participants Amy Figueroa
  • 05/13/2020

NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)

  • NuCana plc (NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. NuCana will work closely with the clinicians involved in NuTide:121 to re-open all of the clinical sites to new patient enrollment as soon as practicable. “We will continue to monitor the impact of the COVID-19 pandemic, but re-opening this study is important for patients with biliary tract cancer who need treatment,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer.
  • 05/05/2020

Got Milk: 12 of 14 infant formula stocks made gains in April, but most are still below pre-COVID levels - Stockhead

  • In April the average infant formula stock gained 21 per cent and only two stocks finished the month in negative territory. Two of the top stocks were recent ASX debutantes Happy Valley Nutrition (ASX:HVM) and Nuchev (ASX:NUC), which gained 93 and 48 per cent respectively.   Happy Valley is at an earlier stage than most other …
  • 05/05/2020

Abba Kyari and the narcissism of our middle class - Businessday NG

  • Around 2012, the federal government initiated a Presidential Special Scholarship for Innovation and Development (PRESSID). Open only to first class graduates of mainly science disciplines from Nigerian universities and following a highly competitive selection process, the recipients were expected to study up to PhD levels at the top 25 universities in the world. They signed a […]
  • 04/23/2020

Prof. Mu’azu Gusau appointed VC of Zamfara Varsity

  • The governor of Zamfara State Bello Matawalle  has approved the appointment of Prof. Mu’azu Gusau as the substantive Vice-Chancellor of the Zamfara State University, Talata-Mafara (ZAMSUT). This wa…
  • 04/19/2020

Update now! Windows zero-day flaws fixed in Patch Tuesday

  • …and there are fixes for Adobe, Oracle and Intel products too. Go get your updates!
  • 04/16/2020

The Full Nerd ep. 135: Intel Comet Lake H and Ghost Canyon NUC reviews, ray traced Minecraft

  • In this episode of The Full Nerd, we review Intel's new "Comet Lake H" 10th-gen Core processors for gaming laptops and its radical Ghost Canyon NUC, and explain what you need to know about the ray tracing coming to Minecraft later this week.
  • 04/16/2020
Unlock
NCNA Ratings Summary
NCNA Quant Ranking